Castle Biosciences (CSTL)
NASDAQ:CSTL
Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$25.05
-$0.86(-2.67%)
At close: 4:00 PM EST
$25.05
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $44.28
Previous CloseN/A
Volume108.23K
Average Volume (3M)454.05K
Market Cap
$597.80M
Enterprise Value$612.32M
Total Cash (Recent Filing)$261.69M
Total Debt (Recent Filing)$36.72M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 10, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding30,329,952
10 Day Avg. Volume414,175
30 Day Avg. Volume454,045
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-127.87
Forecast
1Y Price Target
$42.83Price Target Upside70.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.43
Revenue Forecast (FY)$352.40M
Bulls Say, Bears Say
Bulls Say
Commercial Test Volume GrowthSustained high single‑digit to mid‑double digit core volume growth indicates durable clinical adoption of DecisionDx and related assays. Higher, repeatable test volumes strengthen revenue visibility, improve per‑test economics through scale, and underpin multi‑year revenue growth assumptions.
Portfolio & Regulatory ProgressProgress toward an FDA submission and expanding clinical evidence (DecisionDx, TissueCypher, Advanced ADTx validation) represent structural drivers: regulatory clearance and peer‑reviewed utility increase clinician adoption, payer acceptance, and long‑term addressable market expansion.
Strong Balance Sheet & LiquidityA conservative balance sheet with substantial cash and low leverage (debt/equity <0.08) gives durable financial flexibility to fund commercialization, R&D, and potential M&A without near‑term refinancing risk, supporting multi‑period execution despite profit cyclicality.
Bears Say
Profitability VolatilityEarnings have swung from profitability to losses, with adjusted EBITDA still negative and margins compressed versus prior years. Persistent volatility makes sustainable operating leverage uncertain and means management must convert volume growth into consistent margin recovery to deliver durable profits.
Reimbursement & SCC UncertaintyThe business depends on third‑party payor coverage; unresolved LCD timing and contractor silence create structural revenue timing risk. Until formal Medicare coverage decisions arrive, realized reimbursement per test and adoption in certain clinical segments remain uncertain, affecting multi‑period revenue realization.
Free Cash Flow Pressure & Margin HeadwindsSharp FCF deterioration reflects heavier spending, working capital and capacity investments that compress margin conversion of operating cash flow. Sustained elevated investments, higher cost of sales and depreciation can pressure gross and operating margins until scale benefits fully materialize.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $597.80M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Aug 10, 2026 which is in 68 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on May 06, 2026. The company reported -$0.49 earnings per share for the quarter, the consensus estimate of -$0.49 by $0.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.4.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 30,329,952 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.49 in its last earnings report, expectations of -$0.49. Following the earnings report the stock price went down -22.263%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.83 (70.99% Upside)
$42.83 (70.99% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 205.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $210.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.30%
12-Months-Change
Fundamentals
Return on Equity
-2.77%
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum across core products—notably DecisionDx‑Melanoma and TissueCypher—with significant year‑over‑year test volume growth (36% core volumes; 58% TissueCypher) and an uplifted full‑year revenue guide. Profitability metrics improved versus prior year (narrower net loss, improved adjusted EBITDA) and the balance sheet remains solid with ~$261.7M in cash and marketable securities. Key negatives are an adjusted gross margin decline versus the prior comparable period, continued negative adjusted EBITDA (albeit improved), operating cash use in Q1, ongoing reimbursement and timing uncertainty for DecisionDx‑SCC and for broad commercialization of Advanced ADTx, and higher operating costs tied to growth and capacity investments. On balance, the positive commercial traction, raised guidance, improving profitability trends, and healthy liquidity outweigh the remaining execution and reimbursement risks.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$42.83
▲(70.99% Upside)
Technical Analysis
Ownership Overview
1.95% Insiders
9.55% Mutual Funds
29.96% Other Institutional Investors
44.18% Public Companies and
Individual Investors